Bayer submits moxifloxacin NDA for pneumonia

Bayer submitted an NDA to the FDA for IV moxifloxacin to treat community-acquired pneumonia caused by Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Moraxel...